These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7986109)

  • 1. [Clinical pharmacology in development of new anticancer agents].
    Sasaki Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacodynamics of anticancer agents].
    Ohtsu T; Sasaki Y
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1741-9. PubMed ID: 8379667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of population pharmacokinetic approach to clinical evaluation of anticancer agents].
    Tanigawara Y
    Gan To Kagaku Ryoho; 2001 May; 28(5):711-21. PubMed ID: 11383224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches in preclinical and clinical pharmacokinetics.
    Graham MA; Kaye SB
    Cancer Surv; 1993; 17():27-49. PubMed ID: 8137345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early clinical trial of antineoplastic agents--recent perspectives of pharmacological analysis in phase I study].
    Sasaki Y
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):411-4. PubMed ID: 11265416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
    Reife RA
    Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and cancer: successes, failures and future prospects.
    Workman P
    Cancer Surv; 1993; 17():1-26. PubMed ID: 8137337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
    Saeki T
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologically based phase I trials in cancer chemotherapy.
    Newell DR
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):257-75. PubMed ID: 8040140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.
    Rodman JH; Relling MV; Stewart CF; Synold TW; McLeod H; Kearns C; Stute N; Crom WR; Evans WE
    Semin Oncol; 1993 Feb; 20(1):18-29. PubMed ID: 8475406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Principles and practice of clinical phase I studies].
    Hanauske AR
    Onkologie; 2008; 31 Suppl 2():39-45. PubMed ID: 18487868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.